Description
SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetesIn VitroSCO-267 (CHO cells) activates the Gα q, Gα s, and Gα 12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoSCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: N-STZ rats Dosage: 1 or 10 mg/kg Administration: P.o.; Result: Improved insulin sensitivity and exerted sustained glucose-lowering effect.Form:SolidIC50& Target:GPR40